Clovis Oncology (NASDAQ:CLVS) reported Q2 EPS of ($0.50), $0.09 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $32.1 million versus the consensus estimate of $37.03 million.
Clovis Oncology (NASDAQ:CLVS) reported Q2 EPS of ($0.50), $0.09 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $32.1 million versus the consensus estimate of $37.03 million.